- Home
- RRR vs AAPG Comparison
RRR vs AAPG Comparison
Compare RRR & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRR
- AAPG
- Stock Information
- Founded
- RRR 1976
- AAPG 2009
- Country
- RRR United States
- AAPG China
- Employees
- RRR N/A
- AAPG 567
- Industry
- RRR Hotels/Resorts
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- RRR Consumer Discretionary
- AAPG Health Care
- Exchange
- RRR Nasdaq
- AAPG Nasdaq
- Market Cap
- RRR 2.4B
- AAPG 2.2B
- IPO Year
- RRR 2016
- AAPG 2025
- Fundamental
- Price
- RRR $44.40
- AAPG $24.21
- Analyst Decision
- RRR Buy
- AAPG Buy
- Analyst Count
- RRR 14
- AAPG 1
- Target Price
- RRR $54.00
- AAPG N/A
- AVG Volume (30 Days)
- RRR 600.4K
- AAPG 32.5K
- Earning Date
- RRR 05-01-2025
- AAPG 05-20-2025
- Dividend Yield
- RRR 4.51%
- AAPG N/A
- EPS Growth
- RRR N/A
- AAPG N/A
- EPS
- RRR 2.60
- AAPG N/A
- Revenue
- RRR $1,947,975,000.00
- AAPG $134,352,180.00
- Revenue This Year
- RRR $1.86
- AAPG N/A
- Revenue Next Year
- RRR $3.54
- AAPG $389.09
- P/E Ratio
- RRR $17.06
- AAPG N/A
- Revenue Growth
- RRR 9.48
- AAPG 341.77
- 52 Week Low
- RRR $35.09
- AAPG $16.50
- 52 Week High
- RRR $61.73
- AAPG $26.50
- Technical
- Relative Strength Index (RSI)
- RRR 58.15
- AAPG N/A
- Support Level
- RRR $43.16
- AAPG N/A
- Resistance Level
- RRR $44.91
- AAPG N/A
- Average True Range (ATR)
- RRR 1.23
- AAPG 0.00
- MACD
- RRR 0.40
- AAPG 0.00
- Stochastic Oscillator
- RRR 89.26
- AAPG 0.00
About RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.